Rethinking T Cells in Pancreas Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31072844.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1073.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with pancreatic ductal adenocarcinoma do not benefit from checkpoint blockade. However, human tumors harbor evidence of adaptive immunity in clonally expanded T-cell populations. Immune intact modeling of human tumors identifies stromal sequestration as a mechanism of immune escape. Targeting the stroma combined with checkpoint blockade unleashes antitumor immunity.<i>See related article by Seo et al., p. 3934</i>.
Medical subject headings
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms